Ribavirin, but not interferon α-2b, is associated with impaired osteoblast proliferation and differentiation in vitro

Calcified Tissue International

Volumn 75, Issue 2, 2004, Pages 160-168

  Moreira, R O ^a   Balduino A ^a   Martins, H S L H ^a   Reis, J S N ^a   Duarte, M E L ^a   Farias, M L F ^a   Borojevic, R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Hepatitis C; Interferon; Osteoblasts; Ribavirin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALINE PHOSPHATASE; ALPHA2B INTERFERON; BEFERON ALPHA; RIBAV; RIBAVIRIN;

ARTICLE; BONE DENSITY; BONE MINERAL; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL;

ALKALINE PHOSPHATASE; BONE DEVELOPMENT; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON ALFA-2B; OSTEOBLASTS; OSTEOPOROSIS; RIBAVIRIN; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 4444264904     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-004-0175-0     Document Type: Article

References (34)

1. Gow PJ, Mutimer D (2001) Treatment of chronic hepatitis. BMJ 323:1164-1167
2. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, for The International Hepatitis Interventional Therapy Group (1998) Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432
3. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J, for the FIBROVIRC Project Group (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-1137
4. Kjaergard LL, Krogsgaard K, Gluud C (2001) Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 323:1151-1155
5. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inou A, Kato M, Oshima A, Kinoshita Y, Kamada T (2000) Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 87:741-749
6. Tsuneoka K, Tameda Y, Takase K, Nakano T (1996) Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 31:669-678
7. Olsson R, Johansson C, Lindstedt G, Mellström D (1994) Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 29:753-756
8. Gallego-Rojo FJ, Gonzalez-Calvein JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D (1998) Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28:695-699
9. Duarte MPC, Farias MLF, Coelho HSM, Mendonca LMC, Stabnov LMD, Oliveira MCD, Lamy RA, Oliveira DS (2001) Calcium-PTH-vitamin D axis and metabolic bone disease in viral chronic liver disease. J Gastroenterol Hepatol 16:1022-1027
10. Rouillard S, Lane NE (2001) Hepatic osteodystrophy. Hepatology 33:301-307
11. Solis-Herruzo JA, Castellano G, Fernández I, Muñoz R, Hawkins F (2000) Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 33:812-817
12. Trombetti A, Giostra E, Mentha G, Negro F, Rizzoli R (2002) Lack of evidence for ribavirin-induced bone loss. Hepatology 36:255-257
13. Philpott NJ, Turner AJC, Scopes J, Westby M, Marsch JCW, Gordon-Smith EC, Dalgleish AG, Gibson FM (1996) The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87:2244-2251
14. Sherwood SW, Schimke RJ (1995) Cell cycle analysis of apoptosis using flow cytometry. Methods Cell Biol 46:77-97
15. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M, Albrecht J, for The International Hepatitis Interventional Therapy Group (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499
16. Bonkovsky HL, Stefancyk D, McNeal K, Banner BF, Liu Q, Zucker GM, Israel J, Stagias J, Colker J (2001) Comparative effects of different doses of ribavirin plus interferon-α2b for therapy of chronic hepatitis C. Dig Dis Sci 46:2051-2059
17. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht J, for The Hepatitis International Therapy Group (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492
18. Goldestein SR, Martino FP, Cort S (1997) Ribavirin capsules (SCH 18908) investigator's brochure. Schering-Plough Research Institute
19. Fonteles FJS, Paixao JBA, Coelho HSM, Duarte ME, Farias MLF (2002) Effects of ribavirin in combination with either interferon alpha or peginterferon alpha-2b on calcium and bone metabolism in patients with chronic hepatitis C. J Bone Miner Res 17(Suppl 1):S336
20. Tsuda-Futami E, Shioi A, Jono S, Inaba M, Nishizawa Y, Morii H (1998) Lymphoblastoid interferon-a downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor expression in human osteoblastic cells (Saos-2). Bone 23:205-211
21. Goodman GR, Dissanayake IR, Gorodetsky E, Zhou H, Ma YF, Jee WSS, Epstein S (1999) Interferon-α, unlike interferon-γ, does not cause bone loss in the rat. Bone 25:459-463
22. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM (1999) Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokmetic and pharmacodynamic interactions. Br J Clin Pharmacol 46:563-570
23. Chatelut E, Rostaing L, Grégoire N, Payen JL, Pujol A, Izopet J, Houin G, Canal P (1999) A phamacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 47:365-371
24. Glue P (1999) The clinical pharmacology of ribavirin. Semin Liver Dis 19(S1):17-24
25. Kock HJ, Handschin AE (2002) Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation. Clin Appl Thromb Hemost 8:251-255
26. Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA, Mautalen C (2003) Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 34:81-87
27. Narayana K, D'Souza UJA, Rao KPS (2002) The genotoxic and cytotoxic effects of ribavirin in rat bone marrow. Mutat Res 521:179-185
28. Narayana K, D'Souza UJA, Rao KPS (2002) Effect of ribavirin on epididymal sperm count in rat. Indian J Physiol Pharmacol 46:97-101
29. Joksic G, Stankovic M, Vasic V, Cakar M, Jokanovic M (2000) Influence of ribavirin on the micronucleus formation and in vitro proliferation of human lymphocytes. Neoplasma 47:283-287
30. Laughlin CA, Tseng CK (1997) Antiviral agents, RNA viruses other than HIV. In: Wolff ME (ed) Burger's medicinal chemistry and drug discovery. Vol 5. Therapeutic agents 5th ed. Wiley Interscience publication, John Wiley and Son, New York, pp 565-576
31. Jayaram HN, Cooney DA, Grusch M (1999) Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr Med Chem 6:516-574
32. D'Souza UJA, Narayana K (2002) Mechanism of cytotoxicity of ribavirin in the rat bone marrow and testis. Indian J Physiol Pharmacol 46:468-474
33. Rao KPS, Rahiman MA (1989) Cytogenetic effects of ribavirin on mouse bone marrow. Mutat Res 224:213-218
34. Midander J, Revesz L (1980) The frequency of micronuclei as a measure of cell survival in irradiated cell populations. Int J Radial Biol 28:237-242